Oncology

By targeting the physical mechanics of tumors rather than biochemical pathways, Myosin Therapeutics aims to conquer glioblastoma and court investors in NYC.

With breast cancer rates rising among young women, a gamified digital health app is empowering patients to overcome medical age bias and demand early care.

George Millen explores how Montefiore Einstein's newly minted cancer leadership team is turning urban health disparities into a strategic research advantage.

Elephas Biosciences' live-tissue platform achieves 93% accuracy in predicting immunotherapy response, paving a lucrative path for functional precision oncology.

SpotitEarly's Bio-AI platform combines canine scent detection with machine learning to spot early-stage cancer. Will regulatory hurdles stall its 2027 launch?

Virginia Cancer Specialists is expanding its Warrenton footprint, leveraging corporate infrastructure to decentralize clinical trials and ease patient burdens.

A $29 million gift to Sunnybrook Health Sciences Centre accelerates Canada's precision oncology race while highlighting a reliance on private wealth.

Phanes Therapeutics has advanced its first-in-class bispecific antibody into colorectal cancer trials, testing a novel mechanism to bypass systemic toxicity.

Pilatus Biosciences doses its first Hong Kong patient with PLT012, signaling a strategic shift toward metabolic immunotherapies and Asian clinical hubs.

Parabilis Medicines advances its first-in-class beta-catenin inhibitor into a new FAP cohort, signaling a paradigm shift from surgical intervention to systemic prevention.

Orum Therapeutics enters the clinic with a novel degrader-antibody conjugate, aiming to turn a historically toxic mechanism into a targeted lifeline for AML.

Following its 2024 Sanofi spin-off, Inhibrx Biosciences is preparing to unveil pivotal cancer trial data that could validate its multivalent protein platform.

As Novastra Therapeutics prepares to unveil Phase 1 data at ESMO, its supramolecular nanocloak could redefine how we treat checkpoint-resistant solid tumors.

The NMPA approval of a 6-month prostate cancer drug reveals how mid-tier biotechs navigate China's complex healthcare landscape via strategic partnerships.

A new three-tier triage framework aims to protect prostate cancer patients from the lethal cardiovascular risks of life-extending hormone therapies.

CytoDyn is pivoting to oncology with its CCR5 inhibitor leronlimab. Upcoming Phase 2 data at ESMO 2026 could determine the biotech's financial survival.

Alpheus Medical's new clinical trial tackles butterfly glioblastoma, leveraging non-invasive ultrasound and strategic financing to disrupt oncology.

Survival rates for childhood cancer have soared from 25% in the 1960s to 87% today, fueled by precision medicine. Yet, a severe global equity gap persists.

As geopolitical headwinds stall international research, a $12M philanthropic injection is uniting global experts to hack cancer's most elusive mechanisms.

Ahead of a critical 2027 data readout, Moleculin pitches a breakthrough leukemia drug while navigating a precarious financial runway.